FY2018 Earnings Forecast for Hologic, Inc. Issued By Gabelli (HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Gabelli cut their FY2018 earnings per share estimates for shares of Hologic in a report issued on Monday. Gabelli analyst S. Wojda now anticipates that the medical equipment provider will post earnings per share of $2.25 for the year, down from their previous forecast of $2.30. Gabelli also issued estimates for Hologic’s FY2019 earnings at $2.45 EPS, FY2020 earnings at $2.65 EPS and FY2021 earnings at $2.85 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.52 EPS.

HOLX has been the subject of several other research reports. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price objective for the company in a research report on Wednesday, December 20th. Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Friday, January 19th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Stifel Nicolaus cut shares of Hologic from a “buy” rating to a “hold” rating and lowered their price target for the stock from $45.00 to $42.00 in a research report on Friday, February 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $50.00 price target on shares of Hologic in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Hologic currently has an average rating of “Buy” and an average price target of $48.00.

Hologic (HOLX) traded up $0.23 on Wednesday, reaching $38.03. 3,320,700 shares of the company’s stock traded hands, compared to its average volume of 2,926,417. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The firm has a market cap of $10,700.00, a PE ratio of 14.76, a PEG ratio of 1.71 and a beta of 0.77. Hologic has a 52-week low of $35.33 and a 52-week high of $46.80.

A number of institutional investors have recently added to or reduced their stakes in the stock. Endurant Capital Management LP boosted its stake in Hologic by 115.9% during the 4th quarter. Endurant Capital Management LP now owns 222,844 shares of the medical equipment provider’s stock worth $9,527,000 after acquiring an additional 119,641 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in Hologic by 25.9% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 29,110 shares of the medical equipment provider’s stock worth $1,245,000 after acquiring an additional 5,990 shares during the last quarter. EP Wealth Advisors LLC boosted its stake in Hologic by 6.2% during the 4th quarter. EP Wealth Advisors LLC now owns 209,167 shares of the medical equipment provider’s stock worth $8,942,000 after acquiring an additional 12,132 shares during the last quarter. Zeke Capital Advisors LLC bought a new position in Hologic during the 4th quarter worth approximately $357,000. Finally, LPL Financial LLC boosted its stake in Hologic by 18.9% during the 4th quarter. LPL Financial LLC now owns 47,281 shares of the medical equipment provider’s stock worth $2,021,000 after acquiring an additional 7,509 shares during the last quarter. 93.84% of the stock is currently owned by institutional investors and hedge funds.

In related news, VP Karleen Marie Oberton sold 1,023 shares of Hologic stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Namal Nawana acquired 6,600 shares of Hologic stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the purchase, the director now directly owns 6,954 shares in the company, valued at $263,417.52. The disclosure for this purchase can be found here. 0.79% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “FY2018 Earnings Forecast for Hologic, Inc. Issued By Gabelli (HOLX)” was first posted by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://weekherald.com/2018/02/15/fy2018-earnings-forecast-for-hologic-inc-issued-by-gabelli-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply